Matinas BioPharma to Present at the 9th Annual LD Micro Invitational
03 Juin 2019 - 2:05PM
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a
clinical-stage biopharmaceutical company, today announced that
Jerome D. Jabbour, Chief Executive Officer, has been invited to
present at the 9th Annual LD Micro Invitational investor conference
on Tuesday, June 4th at 1:20 PM PT. The event is being held
on June 4-5, 2019 at the Luxe Sunset Boulevard Hotel, in Los
Angeles, California, and is one of the nation's largest independent
conferences for small/micro-cap companies, with more than 1,000
attendees.
As part of his presentation, Mr. Jabbour will
provide a corporate update and will discuss MAT9001, the Company’s
proprietary prescription-only omega-3 fatty acid-based composition.
Matinas is initially developing MAT9001 for the treatment of severe
hypertriglyceridemia (≥ 500 mg/dL). Leveraging the support of a
world class team of external scientific and clinical advisors and
internal clinical and regulatory expertise, Matinas has put in
place a streamlined clinical development program for approval of
MAT9001, while also planning several additional studies designed to
highlight the differentiating features of MAT9001 relative to the
leading therapies in this space.
Additionally, Mr. Jabbour will discuss the
Company’s differentiated lipid nano-crystal (“LNC”) drug delivery
platform, which offers an oral and intracellular drug delivery
solution with potential advantages for a range of therapeutics,
including oligonucleotides and other nucleic acid polymers,
proteins, peptides, vaccines and small molecules such as
amphotericin B, which comprises the Company’s anti-infective
pipeline candidate, MAT2203. In January 2019, Matinas announced its
first research evaluation with an undisclosed top global
pharmaceutical company aimed to evaluate synergistic effects of its
LNC platform delivery technology with the Company’s partner’s
nucleic acid polymer technology. Matinas recently announced its
second research collaboration with ViiV Healthcare, a global
specialist HIV company established in November of 2009 by
GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to
delivering advances in the treatment and care for people living
with HIV and for people who are at risk of becoming infected with
HIV, to evaluate the use of Matinas’ LNC platform delivery
technology in the antiviral space.
A live audio webcast of the presentation will be
available on the Events page of the Investors section of the
Company’s website (www.matinasbiopharma.com). A webcast replay will
be accessible for 90 days following the live presentation.
About Matinas BioPharma
Matinas BioPharma is a clinical-stage
biopharmaceutical company focused on creating value through the
streamlined development of MAT9001 for the treatment of
cardiovascular and metabolic conditions and the application of its
lipid nano-crystal (“LNC”) platform technology to solve complex
challenges relating to the safe and effective delivery of small
molecules, gene therapies, proteins, peptides and vaccines.
The Company is actively pursuing the development
of MAT9001 with the support of a world-class team of clinical key
opinion leaders and regulatory consultants. MAT9001 is a
prescription-only omega-3 fatty acid-based composition, comprised
primarily of EPA and DPA, under development for
hypertriglyceridemia, which has shown superiority versus Vascepa®
(icosapent ethyl) in reducing serum triglycerides, Total- and
Non-HDL-Cholesterol, apolipoprotein CIII and PCSK9 levels.
In addition, the Company's proprietary,
disruptive technology utilizes lipid nano-crystal cochleates to
encapsulate small molecules, nucleic acid polymers, vaccines and
other medicines potentially making them safer, more tolerable, less
toxic, and orally bioavailable.
For more information, please visit
www.matinasbiopharma.com and connect with the Company on Twitter,
LinkedIn and Facebook.
Matinas Forward-Looking
Statements: This release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995, including those relating to the Company's
strategic focus and the future development of its product
candidates, the anticipated timing of regulatory submissions, the
anticipated timing of clinical studies, the anticipated timing of
regulatory interactions, the Company’s ability to identify and
pursue development and partnership opportunities for its products
or platform delivery technology on favorable terms, if at all, and
the ability to obtain required regulatory approval and other
statements that are predictive in nature, that depend upon or refer
to future events or conditions. All statements other than
statements of historical fact are statements that could be
forward-looking statements. Forward-looking statements include
words such as "expects," "anticipates," "intends," "plans,"
"could," "believes," "estimates" and similar expressions. These
statements involve known and unknown risks, uncertainties and other
factors which may cause actual results to be materially different
from any future results expressed or implied by the forward-looking
statements. Forward-looking statements are subject to a number of
risks and uncertainties, including, but not limited to, our ability
to obtain additional capital to meet our liquidity needs on
acceptable terms, or at all, including the additional capital which
will be necessary to complete the clinical trials of our product
candidates; our ability to successfully complete research and
further development and commercialization of our product
candidates, including MAT2203 and MAT9001; the uncertainties
inherent in clinical testing; the timing, cost and uncertainty of
obtaining regulatory approvals; our ability to maintain and derive
benefit from the Qualified Infectious Disease Product (QIDP),
Orphan and/or Fast Track designations for MAT2203, which does not
change the standards for regulatory approval or guarantee
regulatory approval on an expedited basis, or at all; our ability
to protect the Company's intellectual property; the loss of any
executive officers or key personnel or consultants; competition;
changes in the regulatory landscape or the imposition of
regulations that affect the Company's products; and the other
factors listed under "Risk Factors" in our filings with the SEC,
including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to
place undue reliance on such forward-looking statements, which
speak only as of the date of this release. Except as may be
required by law, the Company does not undertake any obligation to
release publicly any revisions to such forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. Matinas BioPharma's
product candidates are all in a development stage and are not
available for sale or use.
Investor Contact Matinas Biopharma Jenene Thomas
Jenene Thomas Communications, LLC Phone: +1 (833) 475-8247 Email:
mtnb@jtcir.com |
|
Source: Matinas BioPharma Holdings, Inc.
Pfizer (NYSE:PFE)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Pfizer (NYSE:PFE)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024